Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRAX-562 in pediatric SCN2A and SCN8A developmental and epileptic encephalopathies
NCT05818553Phase 3Active, not recruiting
- Sponsor
- Praxis Precision Medicines
- Start
- Aug 2023
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of relutrigine in developmental and epileptic encephalopathy (DEE) (4 arms), sponsored by Praxis Precision Medicines. Primary endpoints: Safety and Tolerability of PRAX-562 at 16 weeks and Long-term Safety and Tolerability of PRAX-562 at 48 weeks. Started Aug 2023; status: active, not recruiting.
02
Drugs
relutrigine
03
Conditions
developmental and epileptic encephalopathy (DEE)
Beyond the preview
Go deeper on NCT05818553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05818553.